SCHEMBL1827084

SCHEMBL1827084

O=c1[nH]n(Cc2ccccc2)c2cc(Cl)c(NS(=O)(=O)c3ccc(F)c(C(F)(F)F)c3)cc12

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CCR9 P51686 2/20 0.49
CCR2 P41597 11/20 0.47
PGAM1 P18669 2/20 0.44
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.39
MMP7 P09237 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3906370 0.93 PGAM1 (0.47) CCR9CCR2PGAM1TP53MAPT
SCHEMBL3911597 0.93 CCR9 (0.46) CCR9CCR2PGAM1TP53MAPT
SCHEMBL3904617 0.91 CCR2 (0.46) CCR9CCR2PGAM1MAPT
SCHEMBL1822618 0.90 MEN1 (0.47) TP53MAPTSMN1; SMN2POLB
SCHEMBL3908733 0.88 CCR2 (0.50) CCR9CCR2PGAM1
SCHEMBL1812321 0.86 PTPN2 (0.49) CCR9CCR2PGAM1TP53MAPT
SCHEMBL3906712 0.86 MEN1 (0.47) CCR2
SCHEMBL1812383 0.85 SLC22A12 (0.48) MAPT
SCHEMBL3917135 0.84 PGR (0.48) CCR2
SCHEMBL3906458 0.82 ACLY (0.47) CCR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101027286-B Indazolone derivatives as 11b-HSD1 inhibitors HOFFMANN LA ROCHE 2011-05-25 CN claimed
JP-4682207-B2 2011-05-11 JP claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US claimed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
CN-101027286-A Indazolone derivatives as 11 b-HSD 1 inhibitors HOFFMANN LA ROCHE (CH) 2007-08-29 CN claimed
EP-1797042-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-06-20 EP claimed
WO-2006034804-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-04-06 WO claimed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US claimed
CN-101027286-B Indazolone derivatives as 11b-HSD1 inhibitors HOFFMANN LA ROCHE 2011-05-25 CN disclosed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
CN-101027286-A Indazolone derivatives as 11 b-HSD 1 inhibitors HOFFMANN LA ROCHE (CH) 2007-08-29 CN disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 CCR9 3101/4885CCR2 3797/4885PGAM1 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.